IBIO supply chain intelligence for iBio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RUBRYC | RUBRYC | 92% | iBio also entered into a Stock Purchase Agreement with RubrYc whereby we purchased 1,909,563 shares of RubrYc's Series A-2 preferred stock |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candida… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS g… |
| KROS | Keros Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| SKYE | Skye Bioscience, Inc. | 72% | Reciprocal relationship from SKYE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from SKYE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from SKYE g… |
| SKYE | Skye Bioscience, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. … |
| TWST | Twist Bioscience Corporation | 72% | as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. Our research and development activities take place primarily at our facilities in … |
| VKTX | Viking Therapeutics, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutic… |
| WVE | Wave Life Sciences Ltd. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ALNY g… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR g… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMY grap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candi… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: icantly more experience commerciali… |
| CLDX | Celldex Therapeutics, Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the … |
| GILD | Gilead Sciences, Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| JNJ | Johnson & Johnson | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS g… |
| KROS | Keros Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| LLY | Eli Lilly and Company | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| MRK | Merck & Co., Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TERN g… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| TWST | Twist Bioscience Corporation | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TWST g… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| VKTX | Viking Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| CHARDAN-CAPITAL-MARKETS-LLC | CHARDAN-CAPITAL-MARKETS-LLC | 62% | range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, … |
| CRAIG-HALLUM-CAPITAL-GROUP-LLC | CRAIG-HALLUM-CAPITAL-GROUP-LLC | 62% | range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, … |
| RUBRYC-THERAPEUTICS-INC | RUBRYC-THERAPEUTICS-INC | 62% | roperty including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) Coll… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IBIO-DEBT-10165 | Warrants outstanding: 9595002 | 90% | xbrl warrant detail from xbrl 2024-06-30. |
| IBIO-DEBT | Debt stack $2.3M | 90% | Market cache reports total debt of $2.3M. |
| IBIO-DEBT-10166 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-06-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IBIO-OWNER-AFFINITY-ASSET-ADVISORS-LLC | Affinity Asset Advisors, LLC | 90% | 13F overlay lists Affinity Asset Advisors, LLC as top holder; 53 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 |